
Core Viewpoint - Zynex, Inc. is facing allegations of issuing materially false and misleading statements regarding its business practices, particularly related to inflated revenue and improper product shipments during the class period from March 13, 2023, to March 11, 2025 [1]. Group 1: Allegations Against Zynex, Inc. - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [1]. - The positive statements made by the defendants regarding the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased shares of ZYXI during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is May 19, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].